MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Molecular Diagnostics

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jmoldx.2013.10.008PMID 24378251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

  2013cited by this paper
• Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

  2013cited by this paper
• Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature.

  2013cited by this paper
• A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

  2013cited by this paper
• Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer.

  2012cited by this paper
• Critical steps in tissue processing in histopathology.

  2012cited by this paper
• Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

  2011cited by this paper
• First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations

  2011cited by this paper
• Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue

  2011cited by this paper
• Gene expression profiling of RNA extracted from FFPE tissues: NuGEN technologies' whole-transcriptome amplification system.

  2011cited by this paper
• Formalin Fixation at Low Temperature Better Preserves Nucleic Acid Integrity

  2011cited by this paper
• Clinical utility of the 70-gene MammaPrint profile in a Japanese population.

  2010cited by this paper
• The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

  2010cited by this paper
• Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature

  2010cited by this paper
• American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer

  2010cited by this paper
• Detection of Prostate Cancer Biomarkers by Expression Microarray Analysis of Transplex® WTA2-Amplified FFPE Tissue RNA

  2010cited by this paper
• The future of diagnostic gene-expression microarrays: bridging the gap between bench and bedside.

  2010cited by this paper
• The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

  2009cited by this paper
• Validation of 70-gene prognosis signature in node-negative breast cancer

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort

  2008cited by this paper
• RNA expression analysis from formalin fixed paraffin embedded tissues

  2008cited by this paper
• Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities.

  2007cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Converting a breast cancer microarray signature into a high-throughput diagnostic test

  2006cited by this paper
• Technology Insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer

  2005cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• The measurement of observer agreement for categorical data.

  1977cited by this paper

• Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).

  2025cites this paper
• MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data

  2025cites this paper
• BRCAGenie: A machine learning-driven 43-gene polygenic risk score model for precision prediction of breast cancer survival

  2025cites this paper
• Preventive, Personalized, and Precision Medicine and Biomarkers for Breast Cancer Diagnosis: Artificial Intelligence Framework

  2025cites this paper
• The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy

  2024cites this paper
• Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue

  2024cites this paper
• Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial.

  2024cites this paper
• B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer

  2023cites this paper
• The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?

  2022cites this paper
• Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.

  2022cites this paper
• High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer

  2021cites this paper
• Title: High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resect ion specimen s in early-stage breast cancer

  2021cites this paper
• Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review

  2021cites this paper
• MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

  2021cites this paper
• The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

  2021cites this paper
• Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer – Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT)

  2021cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer

  2020cites this paper
• Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

  2020cites this paper
• Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer

  2020cites this paper
• Large scale, robust, and accurate whole transcriptome profiling from clinical formalin-fixed paraffin-embedded samples

  2020cites this paper
• The prognostic and predictive role of 21‐gene recurrence scores in hormone receptor‐positive early‐stage breast cancer

  2020cites this paper
• RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery

  2019cites this paper
• Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

  2019cites this paper
• A comparative analysis of RNA sequencing methods with ribosome RNA depletion for degraded and low-input total RNA from formalin-fixed and paraffin-embedded samples

  2019cites this paper
• Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer

  2019cites this paper
• Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining.

  2019cites this paper
• Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer

  2019cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : February 1 , 2019

  2019cites this paper
• Mammaprint™: a comprehensive review.

  2019cites this paper
• Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

  2019influential citation
• Mexican Consensus on diagnosis and treatment of breast cancer

  2019cites this paper
• MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology.

  2019cites this paper
• Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer

  2019cites this paper
• Gene Arrays, Prognosis, and Therapeutic Interventions

  2019cites this paper
• Atlas of RNA sequencing profiles for normal human tissues

  2019cites this paper
• Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

  2019cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : August 1 , 2018

  2018cites this paper
• Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer

  2018cites this paper
• Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.

  2018cites this paper
• Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer

  2018cites this paper
• Histomorphological and Molecular Assessments of the Fixation Times Comparing Formalin and Ethanol-Based Fixatives

  2018cites this paper
• Clinical and molecular aspects of breast cancer: Targets and therapies.

  2018cites this paper
• Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival

  2018cites this paper
• Development of cancer diagnostics—from biomarkers to clinical tests

  2018cites this paper
• Endocrine Therapy for Breast Cancer

  2018cites this paper
• Genomic Applications in Breast Carcinoma

  2018cites this paper
• Genexpressionsanalysen bei Patientinnen mit frühem Brustkrebs

  2018cites this paper
• Prognostic factors in breast cancer with a focus on the role of tumour proliferation

  2018cites this paper
• Molecular Profiling of Breast Cancer and DCIS

  2018cites this paper
• [Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Effective : March 1 , 2018

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : January 1 , 2019

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Effective : July 1 , 2018

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : November 1 , 2018

  2018cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer

  2018cites this paper
• MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer

  2017cites this paper
• Denaturing fixatives are compatible with the NanoString nCounter® platform and the Prosigna® assay.

  2017cites this paper
• Genomic Testing in the Management of Early-Stage Breast Cancer.

  2017cites this paper
• [Validation and clinical application of MammaPrint® in patients with breast cancer].

  2017cites this paper
• A novel semi-robotized device for high-precision 18F-FDG-guided breast cancer biopsy.

  2017cites this paper
• Assessment of PAXgene Fixation on Preservation of Morphology and Nucleic Acids in Microdissected Retina Tissue

  2017cites this paper
• Molecular Classification and Testing of Breast Carcinoma

  2017cites this paper
• CD49f Can Act as a Biomarker for Local or Distant Recurrence in Breast Cancer

  2017cites this paper
• Clinical utility of gene-expression signatures in early stage breast cancer

  2017cites this paper
• Original articleA novel semi-robotized device for high-precision 18F-FDG-guided breast cancer biopsyUn nuevo dispositivo semirrobotizado para biopsia de alta precisión guiada por la captación de 18F-FDG en el cáncer de mama

  2017cites this paper
• Genexpressionsanalysen bei Patientinnen mit frühem Brustkrebs

  2017cites this paper
• A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers

  2017cites this paper
• Utilization of Genomics for Risk Assessment and Molecular Subtyping to Improve Treatment Strategy in Breast Cancer

  2017cites this paper
• Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

  2017cites this paper
• Genexpressionsanalysen bei Patientinnen mit frühem Brustkrebs

  2017cites this paper
• Contemporary challenges in molecular oncology and pathology of the breast

  2017cites this paper
• Validación y aplicación clínica de MammaPrint® en pacientes con cáncer de mama

  2017cites this paper
• Classification et signatures moléculaires des cancers du sein en 2017

  2017cites this paper
• Genomic Testing in Women with Early-Stage Hormone Receptor – Positive , HER 2-Negative Breast Cancer

  2017cites this paper
• Breast Cancer Molecular Diagnostics in Breast Cancer Routine Practice

  2017cites this paper
• Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?

  2017cites this paper
• Selección de la terapia sistémica adyuvante postoperatoria para cáncer de mama en etapa temprana : Una evaluación crítica de las pruebas de expresión génica disponibles comercialmente

  2017cites this paper
• Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

  2017cites this paper
• Novel biomarkers in cancer: The whole is greater than the sum of its parts.

  2017cites this paper
• Predicting Risk of Disease Recurrence

  2016cites this paper
• Current Standard Clinical Predictive Markers

  2016cites this paper
• Genomic profiling of breast cancer in African-American women using MammaPrint

  2016cites this paper
• OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.

  2016cites this paper
• Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis

  2016cites this paper
• Cáncer de mama: determinación del perfil genético a partir de la biopsia percutánea ecoguiada diagnóstica

  2016cites this paper
• Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

  2016cites this paper
• Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?

  2016cites this paper
• Validated biomarkers: The key to precision treatment in patients with breast cancer.

  2016cites this paper
• Expression of proliferation genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast carcinomas. Feasibility and relevance for a routine histopathology laboratory

  2016cites this paper
• Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation

  2016cites this paper
• Equivalence of MammaPrint array types in clinical trials and diagnostics

  2016influential citation
• Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.

  2016cites this paper
• RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining

  2016cites this paper
• Breast cancer: determining the genetic profile from ultrasound-guided percutaneous biopsy specimens obtained during the diagnostic workups.

  2016cites this paper
• Breast cancer: Determining the genetic profile from ultrasound-guided percutaneous biopsy specimens obtained during diagnostic workups☆

  2016cites this paper
• Quality assurance for multiplexed assays – how can it be achieved?

  2016cites this paper
• Breast Cancer Molecular Testing for Prognosis and Prediction

  2016cites this paper
• Biomarker und Risikoabschätzung beim Mammakarzinom

  2015cites this paper
• Specimens for Molecular Testing in Breast Cancer

  2015cites this paper
• Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer.

  2015cites this paper